Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous stem cell therapy - Regeneration Biomedical

Next Previous
Drug Profile

Autologous stem cell therapy - Regeneration Biomedical

Alternative Names: Autologous adipose-derived stem cells - Regeneration Biomedical; RB-ADSC

Latest Information Update: 13 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneration Biomedical
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease
  • Research Amyotrophic lateral sclerosis; Multiple sclerosis; Stroke; Traumatic brain injuries

Most Recent Events

  • 05 May 2025 Interim efficacy and adverse event data from a phase I trial in Alzheimer's disease released by Regeneration Biomedical
  • 29 Oct 2024 Efficacy data from a phase I trial in Alzheimer's disease were released by Regeneration Biomedical
  • 28 Jul 2024 Regeneration Biomedical plans to files an IND application with the US FDA for phase II trials in Alzheimer's disease, Multiple sclerosis, Parkinson’s disease, Chronic traumatic encephalopathy, and Amyotropic lateral sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top